Zepbound cost savings; ivonescimab biliary

Two pieces of industry news landed this week that are worth reading together. First, a real-world matched cohort study published in Diabetes, Obesity and Metabolism found that adults aged over 55 using Zepbound (tirzepatide) had meaningfully lower monthly healthcare costs than matched non-users over 18 months^[1]. Second, ivonescimab, the bispecific antibody co-developed by Summit Therapeutics and Akeso, reported a Phase 3 survival benefit in biliary tract cancer, a disease where no immunotherapy-plus-chemotherapy regimen had previously shown that kind of result^[3].

The Zepbound cost study: what it found

The analysis (Upadhyay et al., published August 2026) drew on US claims data covering November 2022 through September 2025^[1]. Researchers matched 15,843 tirzepatide users to 15,843 non-users on age, sex, baseline body mass index, and comorbidity profile. The population: adults aged over 55 with obesity or overweight but without a diabetes diagnosis, a group that tends to be underrepresented in cost-effectiveness models.

At six months, tirzepatide users had monthly per-patient costs that were up to $181 lower than matched controls. By twelve months, that gap had widened to $607 per month^[1]. The mechanism the authors point to is reduced inpatient hospital stays and emergency-room visits. Eli Lilly's executive vice president Ilya Yuffa described the finding as showing that treatment costs can be more than offset by savings elsewhere in care.

What to hold in mind when reading this

The observation window is tight. Zepbound (tirzepatide for weight management) only received FDA approval in November 2023, so the dataset captures at most about 22 months of Zepbound-era use. Real-world claims studies also cannot fully control for unmeasured differences between users and non-users: people who stay on a weight-loss drug for 18 months are, by definition, a selected group. The study does not report long-term outcomes such as mortality or cardiovascular events. What it does add is a concrete, dollar-denominated signal that aligns with the mechanistic expectation from the obesity-medicine literature: less body weight tends to mean fewer weight-related admissions.

Zepbound is a prescription-only medicine approved by the FDA for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity^[2]. It is the same molecule as Mounjaro (tirzepatide), prescribed under the diabetes indication. The cost figures in the Upadhyay study apply to the Zepbound population specifically: non-diabetic adults with obesity.

The ivonescimab result: a different story in oncology

Ivonescimab is not a peptide and does not belong to the GLP-1 class. It is a bispecific antibody that targets both PD-1 (the immune checkpoint already exploited by approved immunotherapies) and VEGF (a protein that promotes tumour blood-vessel growth). Summit Therapeutics and Akeso have been running a Phase 3 trial in first-line advanced biliary tract cancer^[3].

The trial's data-monitoring committee called an early stop this week based on efficacy: ivonescimab plus chemotherapy showed a clinically meaningful and statistically significant improvement in overall survival compared with durvalumab plus chemotherapy^[3]. Secondary endpoints for tumour progression and response rates were also met. According to BioPharma Dive, this is the first time any therapy has shown a survival benefit over an immunotherapy-chemotherapy combination in this cancer setting. Summit's share price climbed 14% on the news.

Why mention this in a peptide-focused context

Two reasons. First, ivonescimab has already generated the largest Phase 3 readout in non-small cell lung cancer of 2024 and 2025, and the biliary tract result extends the dataset. A growing number of readers following the GLP-1 and obesity-medicine space are also tracking the broader oncology pipeline because of the documented overlap between obesity, metabolic disease, and cancer risk. Second, the biliary tract result, if it leads to approval, would be the first immunotherapy approval in that cancer type to outperform a durvalumab-based regimen, which is a meaningful clinical milestone in its own right.

The McKesson deal and J&J approval: briefly

The same news cycle also carried two other items. McKesson agreed to acquire Precision Medicine Group for $2.25 billion, a move that expands its commercialisation infrastructure for specialty drugs, relevant context given how dependent GLP-1 market growth is on downstream logistics and specialty pharmacy networks^[3]. And the FDA approved J&J's Imaavy for warm autoimmune hemolytic anemia, making it the first approved treatment for that condition. Neither directly touches the peptide or incretin space, but both illustrate the scale of deal-making happening across the sector in mid-2026.

Where this sits for readers of this site

The Zepbound cost study adds to a body of real-world evidence that tirzepatide reduces downstream health system use, not just body weight. The limitation is that it covers a commercially insured, predominantly US population, and the window is still short. The ivonescimab result is a separate story, but one worth noting for anyone following the broader oncology-metabolic intersection. Neither result changes the regulatory picture for tirzepatide in the countries we cover: it remains prescription-only across the EU, EEA, UK, and US, and not approved for self-directed use without a prescriber.

This article is educational. We do not advise on starting, stopping, or sourcing any medicine. Those decisions belong with a clinician who knows your history.